The Effects of a Sub-Anaesthetic Dose of Ketamine on Human Selective Attention

A growing number of studies demonstrate that antagonists of the N-methyl-D-aspartate (NMDA) receptors can induce a broad range of psychophysiological anomalies in healthy subjects similar to those observed in schizophrenia. In this study, the effect of a sub-anaesthetic dose of the non-competitive NMDA antagonist, ketamine, on human selective attention was explored. It was hypothesized that ketamine would induce in healthy subjects psychophysiological anomalies that are commonly observed in schizophrenic patients, such as reduced P300 amplitude and a reduction of both mismatch negativity (MMN) and processing negativity (PN). In a double-blind randomized placebo-controlled design, healthy male volunteers (n = 18) were challenged with a sub-anaesthetic dose of ketamine (0.3 mg/kg iv) after which they were tested in a selective attention task. In this task, two types of stimuli were evenly presented to the left or right ear: standard tones (80%) and deviant tones (20%) of either 1000 or 1100 Hz. The duration of a stimulus (95 dB) was 50 ms, the interstimulus intervals were randomized between 1750 and 2150 ms. The volunteer was instructed to push a button as quickly as possible after hearing the deviant tone in a specified ear. Ketamine did not alter performance of the subjects: in both the placebo and drug condition their reaction times for and percentages of hits and false alarms did not differ. Ketamine did, however, reduce PN and the P300 amplitude (both in general and to deviant stimuli in particular). However, no drug effect on MMN was found. In addition, ketamine enhanced the N100 amplitude to deviant stimuli. In conclusion, ketamine induces some of the attentional deficits in healthy controls that are observed in schizophrenic patients. Consequently, reduced glutamatergic activity in the brain may be involved in some of the symptoms of schizophrenia.

[1]  T. Picton,et al.  Schizophrenia: a neurophysiological evaluation of abnormal information processing. , 1983, Science.

[2]  E. Domino,et al.  Pharmacologic effects of CI‐581, a new dissociative anesthetic, in man , 1965, Clinical pharmacology and therapeutics.

[3]  A. Mcghie,et al.  Disorders of attention and perception in early schizophrenia. , 1961, The British journal of medical psychology.

[4]  J. Kenemans,et al.  Removal of the ocular artifact from the EEG: a comparison of time and frequency domain methods with simulated and real data. , 1991, Psychophysiology.

[5]  P. Tueting,et al.  Auditory evoked potentials, clinical vs. research applications , 1997, Psychiatry Research.

[6]  J. Grotta,et al.  Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial. , 1995, Stroke.

[7]  D. Javitt,et al.  Impairment of early cortical processing in schizophrenia: An event-related potential confirmation study , 1993, Biological Psychiatry.

[8]  R. Näätänen,et al.  Attention and mismatch negativity. , 1993, Psychophysiology.

[9]  A. Malhotra,et al.  Effects of Ketamine on Thought Disorder, Working Memory, and Semantic Memory in Healthy Volunteers , 1998, Biological Psychiatry.

[10]  Heikki Lyytinen,et al.  The Orienting Response in Information Processing , 2002 .

[11]  J. Endicott,et al.  A diagnostic interview: the schedule for affective disorders and schizophrenia. , 1978, Archives of general psychiatry.

[12]  H. Engeland,et al.  Event-related potentials and performance of attention-deficit hyperactivity disorder: Children and normal controls in auditory and visual selective attention tasks , 1997, Biological Psychiatry.

[13]  R. Näätänen The role of attention in auditory information processing as revealed by event-related potentials and other brain measures of cognitive function , 1990, Behavioral and Brain Sciences.

[14]  S. Hillyard,et al.  The effects of channel-selective attention on the mismatch negativity wave elicited by deviant tones. , 1991, Psychophysiology.

[15]  R. Näätänen,et al.  Auditory frequency discrimination and event-related potentials. , 1985, Electroencephalography and clinical neurophysiology.

[16]  P. Michie,et al.  Auditory Selective Attention and Event-Related Potentials in Schizophrenia , 1991, British Journal of Psychiatry.

[17]  R. Kahn,et al.  The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects , 1998, Psychopharmacology.

[18]  G. Rosenbaum,et al.  Model psychoses and schizophrenia. , 1962, The American journal of psychiatry.

[19]  J. Kleinman,et al.  Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. , 1995, Archives of general psychiatry.

[20]  T. Picton,et al.  The N1 wave of the human electric and magnetic response to sound: a review and an analysis of the component structure. , 1987, Psychophysiology.

[21]  C. Tamminga,et al.  Absence of ketamine effects on memory and other cognitive functions in schizophrenia patients. , 1996, Journal of psychiatric research.

[22]  D. Cyril D’Souza,et al.  Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans , 1998, Psychopharmacology.

[23]  R. Oades,et al.  Impaired attention-dependent augmentation of MMN in nonparanoid vs paranoid schizophrenic patients: A comparison with obsessive-compulsive disorder and healthy subjects , 1997, Biological Psychiatry.

[24]  G. Ellison The N-methyl-d-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias , 1995, Brain Research Reviews.

[25]  S. Hillyard,et al.  Modulation of early auditory processing during selective listening to rapidly presented tones. , 1991, Electroencephalography and clinical neurophysiology.

[26]  N C Andreasen,et al.  The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. , 1992, Archives of general psychiatry.

[27]  W. Pritchard,et al.  Cognitive event-related potential correlates of schizophrenia. , 1986, Psychological bulletin.

[28]  Anil K Malhotra,et al.  Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics , 1997, Neuropsychopharmacology.

[29]  G. Juckel,et al.  Residual symptoms and P300 in schizophrenic outpatients , 1996, Psychiatry Research.

[30]  S. Andrews,et al.  Brain potential evidence for an auditory sensory memory deficit in schizophrenia. , 1995, The American journal of psychiatry.

[31]  Herbert Weingartner,et al.  NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers , 1996, Neuropsychopharmacology.

[32]  H. Westenberg,et al.  Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients , 1996, Biological Psychiatry.

[33]  W Ritter,et al.  Impaired mismatch negativity generation reflects widespread dysfunction of working memory in schizophrenia. , 1995, Archives of general psychiatry.

[34]  N. Mataga,et al.  Neurotransmitters, receptors and neuropeptides in post‐mortem brains of chronic schizophrenic patients , 1988, Acta psychiatrica Scandinavica.

[35]  Tamara Hershey,et al.  Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis , 1999, Neuropsychopharmacology.

[36]  S. Andrews,et al.  Mismatch negativity: An index of a preattentive processing deficit in schizophrenia , 1991, Biological Psychiatry.

[37]  Carol A. Tamminga,et al.  Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.

[38]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[39]  C. Schroeder,et al.  Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. , 1996, Proceedings of the National Academy of Sciences of the United States of America.